Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT07158489

1 development in the corpus

NCT07158489

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 11, 2026 · PHASE 2 TRIAL

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

ClinicalTrials.gov

Phase 2 trial with surrogate endpoint (ORR) in a small, single-arm population; results not yet reported in this registry record.

PreliminaryNCT07158489 Gemcitabine + Ivonescimab NSCLC (advanced Non Small Cell Lung Cancer)

Reported

Planned enrollment47

Study phasePHASE 2

Primary outcome measureObjective response rate (ORR) according to…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support